title: Tacrolimus/mycophenolate mofetil-based immunosuppression in aged kidney transplant. A prospective study.
abstract: BACKGROUND
  At the moment, controversy has arisen about immunosuppression in aged kidney transplant recipients. We present our results on the efficacy and safety of induction treatment based on tacrolimus (FK506) and mycophenolate mofetil (MMF).
  
  
  METHODS
  We performed 72 transplants in patients of 60 years or older. Induction treatment consisted on (FK 506) 0.1 mg/kg/day and MMF 2 gr/day. Antilymphocyte serum was administered with delayed graft function. A total of 54 patients received kidneys from donors over 60 years old.
  
  
  RESULTS
  Cold ischemia time was 16.4 h (S=5.7). Delayed graft function occurred in 35 patients (48.6%). Acute rejection was observed in nine patients (12.5%). Opportunistic infections were found in 19 patients (26.4%). Seven patients died due to sudden death (1), acute myocardial infarction (1), stroke (1), infection (3), and neoplasm (1). At 1, 2, and 3 years, serum creatinine was 145, 163, and 156 mmol/l; patient survival 93%, 90%, and 90%; graft survival 93%, 90%, and 87%; and death-censored graft survival 100%, 100%, and 97%, respectively.
  
  
  CONCLUSIONS
  These immunosuppressive guidelines appear to be efficacious and safe in kidney transplant in elderly recipients.
authors.affiliation: Kidney Transplant Unit, Fundació Puigvert. C/Cartagena 340, Universitat Autònoma de Barcelona, 08025 Barcelona, Spain. rsola@fundacio-puigvert.es
authors.forename: Ricard
authors.initials: R
authors.lastname: Solà
authors.forename: Lluis
authors.initials: L
authors.lastname: Guirado
authors.forename: Joan Manuel
authors.initials: JM
authors.lastname: Díaz
authors.forename: Carmen
authors.initials: C
authors.lastname: Facundo
authors.forename: Ignasi
authors.initials: I
authors.lastname: Gich
authors.forename: Esmirna
authors.initials: E
authors.lastname: Chuy
authors.forename: Antonio
authors.initials: A
authors.lastname: Cabezas
mesh_terms: D000368:Aged; D003404:Creatinine / Q000097:blood; D005260:Female; D006084:Graft Rejection; D006085:Graft Survival; D006801:Humans; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000009:adverse effects / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D011446:Prospective Studies; D016559:Tacrolimus / Q000627:therapeutic use*
chemical_list: D007166:Immunosuppressive Agents; D003404:Creatinine; D009173:Mycophenolic Acid; D016559:Tacrolimus